Success Metrics

Clinical Success Rate
100.0%

Based on 16 completed trials

Completion Rate
100%(16/16)
Active Trials
1(6%)
Results Posted
81%(13 trials)

Phase Distribution

Ph not_applicable
2
11%
Ph phase_2
5
28%
Ph phase_3
7
39%
Ph phase_4
2
11%

Phase Distribution

0

Early Stage

5

Mid Stage

9

Late Stage

Phase Distribution16 total trials
Phase 2Efficacy & side effects
5(31.3%)
Phase 3Large-scale testing
7(43.8%)
Phase 4Post-market surveillance
2(12.5%)
N/ANon-phased studies
2(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

16 of 16 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

18

all time

Status Distribution
Active(2)
Completed(16)

Detailed Status

Completed16
Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 25 (31.3%)
Phase 37 (43.8%)
Phase 42 (12.5%)
N/A2 (12.5%)

Trials by Status

recruiting16%
not_yet_recruiting16%
completed1689%

Recent Activity

Clinical Trials (18)

Showing 18 of 18 trials
NCT06994065Not Applicable

Efficacy of Ferric Carboxymaltose Versus Iron Sucrose in Non-dialysis Dependent Chronic Kidney Disease Patients

Completed
NCT07414199Phase 4

The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department

Not Yet Recruiting
NCT07359599Phase 4

The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension

Recruiting
NCT06958822

Ferric Carboxymaltose Methemoglobinemia Study

Completed
NCT00685815Phase 2

Intravenous Iron Metabolism in Restless Legs Syndrome

Completed
NCT06948864

Evaluate the Outcomes of Ferric Carboxymaltose in Patients With Perioperative Anemia

Completed
NCT02410213Phase 2

A Study to Characterize the PK and PD Profile of IV FCM in Pediatric Subjects 1-17 Years Old With IDA

Completed
NCT04246021Not Applicable

Use of Intravenous Ferric Carboxymaltose in Treatment of Anemia in Cancer Patients Undergoing Chemotherapy

Completed
NCT00981045Phase 3

Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function

Completed
NCT00354484Phase 3

Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients

Completed
NCT01382901Phase 2

Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)

Completed
NCT00317239Phase 3

VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

Completed
NCT00395993Phase 3

Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding

Completed
NCT00982007Phase 3

Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)

Completed
NCT00317226Phase 3

Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

Completed
NCT00703937Phase 3

Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia

Completed
NCT01307007Phase 2

Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding

Completed
NCT01290315Phase 2

Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women

Completed

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18